-

Gilead Sciences Announces Third Quarter 2020 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.68 per share of common stock for the third quarter of 2020. The dividend is payable on September 29, 2020, to stockholders of record at the close of business on September 15, 2020. Future dividends will be subject to Board approval.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Investors
Adam Levy, MBA, Ph.D.
(650) 574-3000

Douglas Maffei, Ph.D.
(650) 574-3000

Industry:

Gilead Sciences, Inc.

NASDAQ:GILD
Release Versions
English

Contacts

Investors
Adam Levy, MBA, Ph.D.
(650) 574-3000

Douglas Maffei, Ph.D.
(650) 574-3000

More News From Gilead Sciences, Inc.

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO’s Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led effor...

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines...

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs. This novel HIV t...
Back to Newsroom